| Jul 3 |
CureVac Enters Into New Licensing Agreement With GSK; to Implement 'Significant' Restructuring; Shares Rise Pre-Bell
|
| Jul 3 |
CureVac to cut 30% of workforce as GSK buys rights to make flu, covid shots
|
| Jul 3 |
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
|
| Jul 3 |
CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
|
| Jul 3 |
GSK buys COVID, influenza vaccines from retrenching CureVac
|
| Jun 24 |
CureVac Announces Voting Results of General Meeting
|
| Jun 6 |
First Human Death From Bird Flu Strain Puts Vaccine Stocks Back On The Map
|
| May 30 |
Third human bird flu case found in U.S.
|
| May 28 |
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
|
| May 26 |
CureVac N.V. (NASDAQ:CVAC) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
|
